U.S. Markets closed


Munich - Munich Delayed Price. Currency in EUR
1.40000.0000 (0.00%)
At close: 08:01AM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4000
Bid1.3200 x N/A
Ask1.4300 x N/A
Day's Range1.4000 - 1.4000
52 Week Range0.9500 - 2.9400
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research

    RVLP: Can’t Take My Eyes Off You

    By John Vandermosten, CFA NASDAQ:RVLP READ THE FULL RVLP RESEARCH REPORT We are initiating coverage of RVL Pharmaceuticals, plc (NASDAQ:RVLP) with a valuation of $3.60 per share. RVL’s lead and only marketed asset is Upneeq®, a product developed to treat acquired blepharoptosis, or low-lying eyelids. Following approval for Upneeq in July 2020, RVL embarked on a structured commercialization effort

  • GlobeNewswire

    RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update

    -- Third quarter 2022 UPNEEQ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 2022, a 59% increase from the end of the second quarter 2022 -- -- Anticipates fourth quarter 2022 UPNEEQ net product sales to grow approximately 20% - 40% over the third quarter 2022, representing sales of approximately $12 - $14 million

  • GlobeNewswire

    RVL Pharmaceuticals plc to Discuss Third Quarter 2022 Financial Results and Provide Commercial Update

    -- Conference call to be held Thursday, November 10, 2022, at 4:30 p.m. ET --BRIDGEWATER, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its third quarter 2022 financial results and provide a commercial update on Thursday, November 10, 2022, after the close of